Showing results (131-140 of 143) with videos related to
Sort By:
Pageof 15
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1997
Molecular characterization and role in T cell activation of staphylococcal enterotoxin A binding to the HLA-DR alpha-chainJ Thibodeau, M Dohlsten, I Cloutier, et al.Proceedings of the National Academy of Sciences of the United States of America|September 13, 1994
Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapyM Dohlsten, L Abrahmsén, P Björk, et al.The EMBO Journal|July 17, 1995
Crystal structure of the superantigen staphylococcal enterotoxin type AE M Schad, I Zaitseva, V N Zaitsev, et al.Frontiers in Health Services|January 31, 2024
Strengthening the policy, implementation, and accountability environment for quality care: experiences from quality of care network countriesBlerta Maliqi, Olive Cocoman, Martin Dohlsten, et al.Cancer Immunology, Immunotherapy : CII|August 1, 1995
Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cellsU Holzer, W Bethge, F Krull, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 29, 1998
Staphylococcal enterotoxin D is a promiscuous superantigen offering multiple modes of interactions with the MHC class II receptorsR Al-Daccak, K Mehindate, F Damdoumi, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1991
A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cellsG Hedlund, M Dohlsten, T Herrmann, et al.Cellular Immunology|May 1, 1996
Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular releaseA G Wingren, O Björkdahl, T Labuda, et al.Vox Sanguinis|August 15, 1998
Targeted superantigens for immunotherapy of haematopoietic tumoursT H Tötterman, C Gidlöf, L Ragnarsson, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual diseaseM P Velders, C M van Rhijn, I M Cornelissen, et al.Pageof 15